Email: cspc@cspc.cn
Media
News Center
Dec. 20
2024
SYS6005 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL
Dec. 12
VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR SYH2039 WITH BEIGENE
Dec. 09
ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF SYHX2011 FOR THE TREATMENT OF ADVANCED BREAST CANCER
Dec. 04
CRB-701 (SYS6002) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA
TEDIZOLID PHOSPHATE TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Nov. 27
ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF USTEKINUMAB INJECTION
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
